Cytosorbents (CTSO) Stock Price, News & Analysis

Company Overview

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America. In the United States, the device received Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of critically ill COVID-19 patients exhibiting a cytokine storm. Clinicians integrate CytoSorb into standard extracorporeal circuits such as continuous renal replacement therapy (CRRT) and cardiopulmonary bypass to optimize blood purification protocols in intensive care units.

Beyond its core sorbent technology, Cytosorbents is advancing a pipeline of next-generation products aimed at drug overdose management and vaccine adjuvant development. The company’s R&D efforts leverage proprietary polymer bead platforms to broaden the applications of hemoadsorption in pharmaceutical safety and immunotherapy. With a global sales and distribution network and strategic partnerships in key markets, Cytosorbents continues to expand clinical evidence to support broader adoption of its blood purification solutions.

Key Stats

• Today's Range: $0.87 to $0.92
• 50-Day Range: $0.84 to $1.20
• 52-Week Range: $0.71 to $1.61
• Volume: 126,255 shs
• Average Volume: 181,980 shs
• Market Capitalization: $57.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Moderate Buy

Cytosorbents Stock Analysis - MarketRank™

Cytosorbents scored higher than 56% of companies evaluated by MarketBeat, and ranked 604th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cytosorbents has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Cytosorbents has a consensus price target of $5.50, representing about 509.8% upside from its current price of $0.90.

Amount of Analyst Coverage

Cytosorbents has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cytosorbents are expected to grow in the coming year, from ($0.30) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytosorbents is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytosorbents is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cytosorbents has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.39% of the float of Cytosorbents has been sold short.

Short Interest Ratio / Days to Cover

Cytosorbents has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Cytosorbents has recently decreased by 6.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytosorbents does not currently pay a dividend.

Dividend Growth

Cytosorbents does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.39% of the float of Cytosorbents has been sold short.

Short Interest Ratio / Days to Cover

Cytosorbents has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Cytosorbents has recently decreased by 6.71%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.89

News Sentiment

Cytosorbents has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cytosorbents this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for CTSO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cytosorbents insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.60% of the stock of Cytosorbents is held by insiders.

Percentage Held by Institutions

Only 32.87% of the stock of Cytosorbents is held by institutions.

CTSO Stock Analysis - Frequently Asked Questions

How have CTSO shares performed this year?

Cytosorbents' stock was trading at $0.91 at the start of the year. Since then, CTSO shares have decreased by 0.9% and is now trading at $0.9020.

How were Cytosorbents' earnings last quarter?

Cytosorbents Corporation (NASDAQ:CTSO) issued its quarterly earnings results on Thursday, August, 7th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The medical research company had revenue of $9.62 million for the quarter, compared to analysts' expectations of $9.79 million. Cytosorbents had a negative trailing twelve-month return on equity of 111.97% and a negative net margin of 25.58%.
Read the conference call transcript.

Who are Cytosorbents' major shareholders?

Top institutional shareholders of Cytosorbents include Avenir Corp (8.06%), Geode Capital Management LLC (0.96%) and Osaic Holdings Inc. (0.21%). Insiders that own company stock include Phillip P Chan, Alan D Sobel, Michael G Bator and Kathleen P Bloch.
View institutional ownership trends.

How do I buy shares of Cytosorbents?

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and Docusign (DOCU).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CTSO
• CIK: 1175151
• Web: www.cytosorbents.com
• Phone: (732) 329-8885
• Fax: 732-329-8650
• Employees: 220
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Cytosorbents: $5.50
• High Price Target: $10.00
• Low Price Target: $1.00
• Potential Upside/Downside: +506.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.72 million
• Net Margins: -25.58%
• Pretax Margin: -31.34%
• Return on Equity: -111.97%
• Return on Assets: -29.00%

Debt

• Debt-to-Equity Ratio: 1.24
• Current Ratio: 2.34
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: $35.60 million
• Price / Sales: 1.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 4.54

Miscellaneous

• Outstanding Shares: 62,760,000
• Free Float: 58,620,000
• Market Cap: $56.92 million
• Optionable: Optionable
• Beta: 1.28